Mar 28, 2018 7:05am EDT Immunovaccine Announces Initiation of Patient Dosing in Investigator-Sponsored Phase 2 Clinical Trial of Its Lead Candidate DPX-Survivac Used in Combination with Pembrolizumab in Patients with DLBCL
Mar 19, 2018 5:05pm EDT Immunovaccine Researchers to Present New Preclinical Data at AACR Annual Meeting 2018
Mar 08, 2018 5:05pm EST Immunovaccine Chief Medical Officer Dr. Gabriela Rosu to Present at the Oncology Meeting Innovations (OMI) Annual Summit on Hematologic Malignancies
Feb 15, 2018 9:00am EST Immunovaccine Announces Closing of $14.375 million Bought Deal Offering with Over-allotment option exercised in full
Jan 31, 2018 7:05am EST Published Study Demonstrates the Association Between Immunovaccine’s Proprietary Immune-targeted Delivery Technology and Enhanced Efficacy in Slowing Tumor Progression